Revium Rx Reports 28% Decrease in Net Loss for Q2 2026

Revium Rx, a biopharmaceutical company focused on developing innovative nano-medicines, reported its financial results for the second quarter of 2026, revealing a net loss of $748,000, a decrease of 28% from the $1,039,000 loss recorded in the same period of 2025. For the first half of 2026, the company reported a net loss of $1,473,000, down from $1,673,000 in the prior year. The reduction in losses is attributed to a decrease in general and administrative expenses, which fell by 47.2% to $289,000 for the second quarter, compared to $547,000 in the same quarter of 2025.

Total operating expenses for the second quarter of 2026 were $732,000, a 22% decrease from $938,000 in the same quarter of the previous year. Research and development expenses increased by 13.3% to $443,000, reflecting ongoing investments in the company's product development pipeline, particularly the Nano-Mupirocin program, which is advancing toward clinical trials. The company has not generated any revenue from product sales to date and continues to rely on external financing to support its operations, with an accumulated deficit of $26.4 million as of June 30, 2026.

In terms of strategic developments, Revium Rx completed a share exchange with Lipovation Ltd. in July 2024, which has since become a wholly owned subsidiary. This acquisition has shifted the company's focus toward developing lipid-based therapies for infectious diseases and cancer. The company is currently working on several product candidates, including a systemic liposomal antibiotic targeting drug-resistant pathogens and other therapies aimed at improving treatment efficacy for oncology and infectious diseases.

Operationally, Revium Rx has faced challenges, including delays in the Nano-Candesartan program due to unresolved contractual matters with Yissum Research Development Company. Additionally, the company is navigating the impacts of regional conflicts in Israel, where its headquarters are located, although these have not yet materially affected its financial performance. As of June 30, 2026, the company had cash and cash equivalents totaling $842,000, down from $1.7 million at the end of 2025, indicating a need for additional capital to sustain its operations.

Looking ahead, Revium Rx aims to advance its Nano-Mupirocin program into clinical development, pending regulatory approvals and completion of ongoing analyses. The company acknowledges the significant risks and uncertainties associated with drug development and the necessity of securing further investments to continue its research and development activities. Management has indicated that without adequate funding, the company may need to scale back or delay its development programs, raising concerns about its ability to continue as a going concern.